SENSORION (EPA:ALSEN) | WebDisclosure

Basculer en Français

8611	Companies
141742	Keywords
77650	Articles
75757	Press releases

Home
Companies
SENSORION

PRESS RELEASE

published on 03/14/2025 at 07:30, 30 days 7 hours ago

Informations privilégiées / Communiqué sur comptes, résultats
Sensorion présente ses résultats financiers pour l’exercice 2024, fait le point sur ses activités et annonce la mise à disposition du rapport annuel. Renforcement financier, essais cliniques avancés

Résultats Financiers Innovation Scientifique Thérapie Génique Études Cliniques Sensorion
PRESS RELEASE

published on 03/14/2025 at 07:30, 30 days 7 hours ago

Inside Information / News release on accounts, results
Sensorion reports full-year 2024 results and provides corporate update with significant milestones achieved in gene therapy clinical trials and financial highlights. Company well positioned for growth in 2025

Clinical Trials Financial Highlights Gene Therapy Full-year Results Sensorion
BRIEF

published on 03/07/2025 at 07:35, 1 month 6 days ago

Sensorion Completes Recruitment for NOTOXIS Trial of SENS-401

Clinical Trial Sensorion SENS-401 Cisplatin Ototoxicity
BRIEF

published on 03/07/2025 at 07:35, 1 month 6 days ago

Sensorion conclut le recrutement pour l'essai NOTOXIS sur le SENS-401

Essai Clinique Sensorion SENS-401 Cisplatine Ototoxicité
PRESS RELEASE

published on 03/07/2025 at 07:30, 1 month 6 days ago

Inside Information / Other news releases
Sensorion completes patient enrollment in NOTOXIS Phase 2a Clinical Trial of SENS-401 for Cisplatin-Induced Ototoxicity prevention, targeting a significant unmet medical need

Clinical Trial Sensorion SENS-401 NOTOXIS Cisplatin-Induced Ototoxicity
PRESS RELEASE

published on 03/07/2025 at 07:30, 1 month 6 days ago

Informations privilégiées / Autres communiqués
Sensorion annonce la fin du recrutement des patients dans NOTOXIS, essai clinique Phase 2a SENS-401 pour prévenir ototoxicité cisplatine. Résultats NOTOXIS attendus fin 2025

Phase 2a Sensorion SENS-401 Ototoxicité NOTOXIS
BRIEF

published on 02/21/2025 at 07:35, 1 month 20 days ago

L'essai clinique SENS-501 de Sensorion progresse avec une recommandation DMC positive

Essai Clinique Thérapie Génique Sensorion Perte Auditive SENS-501
BRIEF

published on 02/21/2025 at 07:35, 1 month 20 days ago

Sensorion's SENS-501 Clinical Trial Progresses with Positive DMC Recommendation

Gene Therapy Clinical Trial Sensorion Hearing Loss SENS-501
PRESS RELEASE

published on 02/21/2025 at 07:30, 1 month 20 days ago

Inside Information / Other news releases
Sensorion receives positive recommendation from Data Monitoring Committee for Audiogene Phase 1/2 clinical trial of SENS-501 gene therapy program to treat congenital deafness linked to OTOF gene mutations

Gene Therapy Sensorion Audiogene Deafness Data Monitoring Committee
PRESS RELEASE

published on 02/21/2025 at 07:30, 1 month 20 days ago

Informations privilégiées / Autres communiqués
Sensorion reçoit une recommandation positive du Comité de Surveillance des Données pour la poursuite de l'essai clinique Audiogene avec le SENS-501. La sécurité du programme de thérapie génique est confirmée. Fin du recrutement de la seconde cohorte prévue pour 2025

Phase 1/2 Sensorion SENS-501 Audiogene Comité De Surveillance

Accesswire

Published on 04/12/2025 at 15:45, 22 hours 57 minutes ago

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presid
Published on 04/12/2025 at 02:00, 1 day 12 hours ago

Battery X Metals Announces Provisional Patent Application with United States Patent & Trademark Office for Lithium-Ion Battery Rebalancing Technology Innovations
Published on 04/12/2025 at 00:10, 1 day 14 hours ago

Applied Minerals, Inc. Files Motion to Approve Disclosure Statement
Published on 04/12/2025 at 00:00, 1 day 14 hours ago

Ur-Energy Releases 2024 Year End Results
Published on 04/11/2025 at 23:45, 1 day 14 hours ago

Gold Terra Closes First Tranche of Financing Package with Support from Osisko Gold Royalties

View all ACCESSWIRE

EQS Group

Published on 04/11/2025 at 21:45, 1 day 16 hours ago

OPPO Unveils Agentic AI Initiative at Google Cloud Next 2025, Showcasing Innovations and Leadership in AI Experiences
Published on 04/11/2025 at 18:40, 1 day 20 hours ago

AGM 2025 - Bossard Holding AG Press Release
Published on 04/11/2025 at 18:38, 1 day 20 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/11/2025 at 18:23, 1 day 20 hours ago

EQS-Adhoc: Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024
Published on 04/11/2025 at 18:10, 1 day 20 hours ago

Kaufman & Broad SA: 2025, 1ST QUARTER RESULTS

Les Echos

Published on 04/11/2025 at 18:30, 1 day 20 hours ago

Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:30, 1 day 20 hours ago

Reclassement d'actions au sein du concert familial Feuillet sans incidence sur le contrôle de la société
Published on 04/11/2025 at 18:00, 1 day 20 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2025
Published on 04/11/2025 at 18:00, 1 day 20 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:50, 1 day 20 hours ago

Mise à disposition du Rapport Financier Annuel 2024

View all LES ECHOS COMFI WIRE